https://doi.org/10.4081/reumatismo.2023.1601

Myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related

Vol. 75 No. 3 (2023)
Published: 18 September 2023
Myositis, SARS-CoV-2 vaccination
Abstract Views: 1132
PDF: 398
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

J. Finsterer
fifigs1@yahoo.de
https://orcid.org/0000-0003-2839-7305
Neurology and Neurophysiology Center, Vienna, Austria.
A.S. MohanaSundaram
https://orcid.org/0000-0002-2483-7679
School of Pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamilnadu, India.
F. Scorza
Department of Neuroscience, Paulista School of Medicine, Federal University of São Paulo, Brazil.

We read with interest the article by Camargo-Coronel et al. reporting on a systematic review of patients with idiopathic, inflammatory myopathy developing after anti-SARS-CoV-2 vaccinations.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Camargo-Coronel A, Quiñones-Moya H, Hernández-Zavala MR, Hernández-Vázquez JR, Vázquez-Zaragoza MÁ. Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review. Reumatismo 2023; 75(1). doi: 10.4081/reumatismo.2023.1548. DOI: https://doi.org/10.4081/reumatismo.2023.1548
Al-Rasbi S, Al-Maqbali JS, Al-Farsi R, Al Shukaili MA, Al-Riyami MH, Al Falahi Z, et al. Myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of pfizer-biontech BNT162b2 mRNA covid-19 vaccine: a case report. Am J Case Rep 2022; 23: e934399. DOI: https://doi.org/10.12659/AJCR.934399
Rodrigues de Carvalho M, Sá de Deus Rocha MM, Alves Bezerra V, de Pontes ME, Del Negro MC, Antunes JS, et al. Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase immune-mediated necrotizing myopathy following mRNA SARS-CoV-2 vaccination. Case Rep Neurol Med 2023; 2023: 7061783. DOI: https://doi.org/10.1155/2023/7061783
Syrmou V, Liaskos C, Ntavari N, Mitsimponas K, Simopoulou T, Alexiou I, et al. Covid-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol Res 2023; 16: 1-10. DOI: https://doi.org/10.1007/s12026-023-09368-2
Chang CH, Gupta R, Setyono D, Cuevas-Ocampo AK, Khoshnoodi MA. Refractory seronegative immune-mediated necrotizing myopathy after receiving mRNA-1273 SARS-CoV-2 vaccine: a case report. J Clin Neuromuscul Dis 2023; 24: 168-9. DOI: https://doi.org/10.1097/CND.0000000000000431
Chan AR, Cohen Tervaert JW, Redmond D, Yacyshyn E, Ferrara G, Hwang PM, et al. A case series of dermatomyositis following SARS-CoV-2 vaccination. Front Med (Lausanne) 2022; 9: 1013378. DOI: https://doi.org/10.3389/fmed.2022.1013378
Shobha V, Rajasekhar L. Current approach to diagnosis of inflammatory myopathies: clinical features and myositis antibody profiles. Indian J Pathol Microbiol 2022; 65: S252-8.

How to Cite

Finsterer, J., MohanaSundaram, A., & Scorza, F. (2023). Myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related. Reumatismo, 75(3). https://doi.org/10.4081/reumatismo.2023.1601
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.